Stuart Lacock has become vice president of North American sales for SciGene, the company said today. He will be responsible for expanding business in the
David Persing will become executive vice president as well as chief medical and technical officer with responsibility for R&D of Cepheid, starting Aug. 29, the company said yesterday. He has been a company director since April 2004 and will remain on the company's board. Most recently, he was senior vice president and CSO of Corixa. Persing holds MD and PhD degrees from the
Rudolph Potenzone has joined CambridgeSoft as vice president of enterprise solutions. He most recently worked at Ingenuity, which he joined last March as senior vice president of business development and strategic planning. Potenzone was previously CEO of Lion Bioscience's
Andrew MacDonald has become head of the new microarray technologies division of Genesis Diagnostics, the Littleport, UK-based company said last week. He used to be a manager with Genomics Solutions.
Steven Enoch has become Peakdale Molecular's computational chemistry department head. Enoch joins the firm from Cyprotex Discovery, where he worked as a chemoinformatician.
David Stone has become chairman of the board of directors of Oscient Pharmaceuticals, the company said last week. He replaces David Singer, who became chairman after the 2004 merger of Genome Therapeutics and GeneSoft Pharmaceuticals that created Oscient, and will remain a board member. Stone has been a company director since 2001. He is a partner at Flagship Venture, a
Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.